David Sans

David Sans, an investment banker with a rich background in chemical engineering, delves into life sciences investment trends. He discusses the critical implications of patent expirations and the resulting opportunities in mergers and acquisitions. Sans highlights the evolving landscape of investments in biotech, including advancements in CAR T cell therapies and geopolitics affecting funding strategies. The conversation also explores the importance of strategic partnerships and collaborative banking, painting a hopeful picture for the future of healthcare investments.